Literature DB >> 16374461

Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis.

Sarah Guégan1, Sylvie Bastuji-Garin, Ewa Poszepczynska-Guigné, Jean-Claude Roujeau, Jean Revuz.   

Abstract

The SCORTEN, calculated within 24 hours of admission, is a severity-of-illness score validated for toxic epidermal necrolysis and Stevens-Johnson syndrome. Our purpose was to assess the performance of successive SCORTEN during the first 5 days of hospitalization and to determine the influence of admission delay. Charts of 144 patients aged 46.8 years (+/-19.7), admitted to our department (1993-2003) with Stevens-Johnson syndrome or toxic epidermal necrolysis, were reviewed. Successive SCORTEN were compared between deceased patients (n = 28, 19.4%) and survivors (n = 116). The performance of the score (calibration, discrimination) was assessed on days 1-5. All seven SCORTEN variables, on days 1-5, were associated with a higher mortality rate. The SCORTEN rose slightly during hospitalization, with a significant difference between days 1 and 4 (<0.05). Performance of the SCORTEN was good on each day, but slightly better on day 3. The areas under the receiver-operating characteristic curves were above 80%. The admission delay did not differ between deceased patients and survivors. Delay-adjusted SCORTEN was close to the crude SCORTEN. The SCORTEN performance during the first 5 days of hospitalization was excellent, and at its best on day 3. We recommend to compute again the SCORTEN on day 3. The admission delay did not influence prognosis or SCORTEN.

Entities:  

Mesh:

Year:  2006        PMID: 16374461     DOI: 10.1038/sj.jid.5700068

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  34 in total

1.  60-year-old man with rash.

Authors:  Devin E Shahverdian; Constantinos P Anastassiades; Joseph C Charles
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

Review 2.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

3.  Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality.

Authors:  Jean-Claude Roujeau; Sylvie Bastuji-Garin
Journal:  Ther Adv Drug Saf       Date:  2011-06

4.  Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.

Authors:  Megan H Noe; Misha Rosenbach; Rebecca A Hubbard; Arash Mostaghimi; Adela R Cardones; Jennifer K Chen; Jonathan Cotliar; Mark D P Davis; Arturo Dominguez; Lindy P Fox; Lauren C Hughey; Benjamin H Kaffenberger; Daniela Kroshinsky; Bernice Y Kwong; Daniel D Miller; Amy Musiek; Alex G Ortega-Loayza; Victoria R Sharon; Kanade Shinkai; Erika M Summers; Karolyn A Wanat; David A Wetter; Scott Worswick; David J Margolis; Joel M Gelfand; Robert G Micheletti
Journal:  JAMA Dermatol       Date:  2019-04-01       Impact factor: 10.282

Review 5.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

6.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

7.  Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis.

Authors:  Hui Kai Koh; Stephanie Fook-Chong; Haur Yueh Lee
Journal:  JAMA Dermatol       Date:  2020-12-01       Impact factor: 10.282

Review 8.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Drug-mediated rash: erythema multiforme versus Stevens-Johnson syndrome.

Authors:  Cassandra Hidajat; Duncan Loi
Journal:  BMJ Case Rep       Date:  2014-09-22

10.  Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme database.

Authors:  Susannah M C George; David A Harrison; Catherine A Welch; Kathleen M Nolan; Peter S Friedmann
Journal:  Crit Care       Date:  2008-01-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.